The US Food and Drug Administration has granted breakthrough therapy designation for United Kingdom-based GlaxoSmithKline's meningitis B vaccine, Bexsero [Meningococcal group B Vaccine (rDNA, component, adsorbed)], it was reported yesterday.
The approval is intended for the development of the vaccine in the prevention of Invasive Meningococcal Disease caused by serogroup B in children 2-10 years of age. It is the first vaccine in the world to receive the Breakthrough Therapy Designation twice.
GSK Vaccines chief scientist, Rino Rappuoli, said, 'This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. GSK is committed to the pursuit of innovative vaccines that help protect against serious diseases with significant unmet need.'
Bexsero is licensed in more than 35 countries.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval